November 2018 ASBMT Monthly Self-Directed Learning Quiz

On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Question Title

* 1. Which of the following statements about hepatic sinusoidal obstructive syndrome (SOS) following hematopoietic cell transplantation is INCORRECT?

A. It is characterized by jaundice, fluid retention and tender hepatomegaly

B. The diagnostic criteria (Modified Seattle and Baltimore) for hepatic SOS has limitations

C. The pathogenesis of SOS is believed to reside at the level of arterial hepatic endothelial cell

D. Defibrotide is treatment of choice for severe SOS

Question Title

* 2. Which of the following statements about second malignancy after hematopoietic cell transplantation is INCORRECT?

A. The risk for non-squamous cell cancers is increased in patients younger than age 30 years who receive radiation therapy

B. The risk for squamous cell cancers is not increased in patients with chronic graft-versus-host disease

C. Children who receive cranial irradiation are at risk for developing brain tumors

D. The risk of post-transplant lymphoproliferative disorders is increased with T cell depletion platform

Question Title

* 3. Which of the following statements about trends of allogeneic hematopoietic cell transplant for malignant diseases in older adults (defined here as >60 years of age) is CORRECT? (CIBMTR data)

A. The trends have increased in all malignant diseases except acute myeloid leukemia

B. The trends have decreased in all malignant diseases except acute myeloid leukemia

C. Overall the trends have increased in acute myeloid leukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma

D. There has been no change in trends in acute myeloid leukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma

Question Title

* 4. Which of the following factor(s) may influence toxicity associated with chimeric antigen receptor (CAR) T cell therapy?

A. Disease type

B. CAR T cell construct

C. Age of the subject

D. All of the above

E. A and B

Question Title

* 5. Which of the following statements about survival after hematopoietic cell transplantation for myelodysplastic syndrome (MDS) is CORRECT? (CIBMTR data)

A. The 3-year probabilities of survival are 52% ± 2% for recipients of sibling donor transplants for early MDS

B. The 3-year probabilities of survival are 49% ± 1% for recipients of unrelated donor transplants for early MDS

C. The 3-year probabilities of survival are 45% ± 1% for recipients of sibling donor transplants for advance MDS

D. The 3-year probabilities of survival are 41% ± 1% for recipients of unrelated donor transplants for advance MDS

E. All of the above